The Influence of NPPA/NPPB Haplotype on Natriuretic Peptide Plasma Levels
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 437
- Locations
- 1
- Primary Endpoint
- Influence of NPPA/NPPB haplotype on natriuretic peptide plasma levels
Study Overview
Brief Summary
Crosssectional study to analyse the genetic influence on levels of cardiac biomarkers (BNP, NT-proBNP).
Detailed Description
Background
Natriuretic peptides play an important role in risk stratification and management of patients undergoing non-cardiac surgery. However, due to genetic variability, the levels of these biomarkers may differ in individual patients with cardiac derangement. In the preoperative setting, genetic contribution to natriuretic peptide plasma level variability has not yet been determined.
Objective
The aim of this study is to assess genetic contribution to NP plasma level variability in a Swiss cohort.
Methods
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •18 years and older
- •Written informed consent
- •Scheduled surgery
- •Exclusion Criteria
- •No informed consent
- •Cognitive impairment
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Influence of NPPA/NPPB haplotype on natriuretic peptide plasma levels
Time Frame: Blood samples collected at start of anesthetic procedure
Estimation of genetic effects on natriuretic peptide (BNP, NT-proBNP) plasma levels
Secondary Outcomes
No secondary outcomes reported